Lombard Medical releases early results from the Altura endograft system clinical evaluation

341

Altura_Medical_AgiliD_MainLombard Medical, has announced the 30-day clinical results from 57 patients that were implanted with the Altura endograft system. The 57 patients were implanted by Albrecht Krämer at the Pontificia Universidad Católica de Chile Hospital in Santiago, Chile, and Dainis Krievins, professor and department head of Vascular and Endovascular Surgery at the Pauls Stradins Clinical University Hospital in Riga, Latvia.


The 30-day follow up data on evaluable patients demonstrated the following;

  • Device delivery success of 98%
  • Freedom from Type I/III endoleaks rate of 98%
  • Freedom from rupture in 100% of patients
  • Freedom from conversion to open procedure in 100% of patients
  • Freedom from graft occlusion in 98% of patients

“Our Altura clinical experience with more than 45 patients has shown the device to be safe, effective, and very easy to use,” said Krämer. “The device also eliminates the need for contralateral cannulation that results in a simple, safe and consistent deployment. From a safety perspective, I appreciate the retrograde delivery of the limb sections of the device that virtually eliminates the possibility of occluding any branch vessels, while having the ability to reposition the device before final deployment. The 14F ultra low profile delivery catheter can also accommodate smaller access vessels that may be compromised due to disease.”